Skip to content

MDMA for PTSD: all studies

Page 19 of 21: studies 181 to 190 of 204, newest first. Back to the MDMA for PTSD overview

Research

MDMA Advances Another Step As Tool to Treat PTSD

Psychiatric News November 30, 2017 Richard Karel

3,4-methylenedioxymethamphetamine (MDMA) holds promise to once again become a therapeutic tool. After 16 years of preliminary clinical trials, the Food and Drug Administration (FDA) in late August gave expedited approval for multiple phase 3 trials of 3,4-methylenedioxymethamphetamine (MDMA) as a potential "breakthrough therapy" for treatment of posttraumatic stress disorder (PTSD). The complex...

DOI: 10.1176/appi.pn.2017.pp10b6 (opens in new tab) MDMA Psilocybin Clinical trial Veterans affairs +3

MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics".

Neuroscience Letters May 10, 2017 Ben Sessa

There is a range of therapies to treat Post Traumatic Stress Disorder (PTSD) but treatment resistance remains high, with many sufferers experiencing the chronic condition. Engagement in trauma-focused psychotherapy is difficult for some patients with PTSD, especially those with extreme affect dysregulation associated with recall of traumatic memories. In recent years there have been a number of...

DOI: 10.1016/j.neulet.2016.07.004 (opens in new tab) Full text (opens in new tab) MDMA PTSD

B-56Investigation of Personality Change Following MDMA-Assisted Psychotherapy for Post Traumatic Stress Disorder

Archives of Clinical Neuropsychology August 31, 2016 Michael Wagner, Michael C Mithoefer, Ann T Mithoefer et al. 1 citation

Objective: New data from a previously published randomized blinded Phase II clinical trial (Mithoefer, et al., 2011) is presented here to test whether psychological change mediates the effect of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for chronic, treatment-resistant PTSD. Method: Twenty-three (23) subjects with treatment-refractory PTSD were randomized to either a...

DOI: 10.1093/arclin/acw043.131 (opens in new tab) Full text (opens in new tab) MDMA Traumatic stress Psychotherapist Clinical psychology +1

Clinical applications of hallucinogens: A review.

Experimental and Clinical Psychopharmacology August 1, 2016 Albert Garcia‐romeu, Brennan Kersgaard, Peter H. Addy 198 citations

Hallucinogens fall into several different classes, as broadly defined by pharmacological mechanism of action, and chemical structure. These include psychedelics, entactogens, dissociatives, and other atypical hallucinogens. Although these classes do not share a common primary mechanism of action, they do exhibit important similarities in their ability to occasion temporary but profound...

DOI: 10.1037/pha0000084 (opens in new tab) Full text (opens in new tab) MDMA PTSD Anxiety Psychedelics: psilocybin +12

Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy

Journal of Psychopharmacology April 26, 2016 Timothy Amoroso, Michael Workman 89 citations

Since the wars in Iraq and Afghanistan, posttraumatic stress disorder (PTSD) has become a major area of research and development. The most widely accepted treatment for PTSD is prolonged exposure (PE) therapy, but for many patients it is intolerable or ineffective. ±3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) has recently re-emerged as a new treatment option, with...

DOI: 10.1177/0269881116642542 (opens in new tab) MDMA Meta-analysis Clinical trial Posttraumatic stress +2

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.

The Lancet Psychiatry April 5, 2016 Michael C Mithoefer, Charles S. Grob, Timothy D Brewerton 237 citations

4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxymethamfetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as...

DOI: 10.1016/s2215-0366(15)00576-3 (opens in new tab) Psychedelic therapy Post-traumatic stress disorder Psychedelic-assisted treatment Psilocybin therapy +27

Can ecstasy treat the agony of PTSD?

European Psychiatry March 1, 2016 M. Mithoefer

IntroductionTwo serotonin reuptake inhibitors (SSRIs) have received FDA indication for treatment of PTSD, however the effectiveness of pharmacotherapy for PTSD is limited. Psychotherapy, including several well established evidence based methods, is the mainstay of PTSD treatment. Despite advances in this area, a significant percentage of PTSD patients are refractory to existing treatments....

DOI: 10.1016/j.eurpsy.2016.01.798 (opens in new tab) PTSD Treatment MDMA-Assisted Therapy Mental health improvement Clinical research

Psychedelic rehabilitation for drug policy and trauma survivors : advancing mental health care by granting access to MDMA-assisted therapy for the treatment of post-traumatic stress disorder

eiuc.gc.repository 2016 Lily Jarrett Pyle

According to current international drug policy, psychedelic drugs share the same abuse and ad-dictability potential as heroin. The presumption is that acknowledging any different would not only pose a threat to the safety and health of society but would compromise established moral values. Legislators have created a campaign against psychedelics since their revival in the 1960s, fighting a war...

DOI: 10.25330/2415 (opens in new tab)